10.1016/s0753-3322(03)00048-9 Biomed
The authors found the glucose infusion rate (GIR) during the clamp study decreased with OXM compared with OXMQ3E in wild-type mice, likely due to increased hepatic glucose output from GCGR agonism with OXM
Based on clinical trial criteria, candidates typically include adults with obesity (BMI 30) or those with a BMI 27 plus weight-related health conditions such as type 2 diabetes, cardiovascular disease, or kidney disease
The attack proceeds unchecked
Macrophage polarisation in osteoarthritis progression: a promising therapeutic target
For vascular dementia, the 2019 Cochrane review pooled six trials and 597 patients and was more encouraging on benefit: a moderate improvement in cognition, a standardized mean difference of 0.36 (0.13 to 0.58), and a benefit on global clinical function, a risk ratio of 2.69 (1.82 to 3.98) (Cui et al., Cochrane 2019)